Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 14Recruiting 3Withdrawn 2Unknown 1Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7Fatigue 3Pain 2Vomiting 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neurotoxicity Syndromes 1Neoplasms 1Multiple Myeloma 1Mucositis 1Lung Neoplasms 1Leukemia 1Ileus 1Hot Flashes 1Hematologic Neoplasms 1Graft vs Host Disease 1Female Breast Cancer 1Depression 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms, Male 1

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Acupuncture Therapy × Clear all
NCT00065234 2017-03-28

Acupuncture to Prevent Postoperative Bowel Paralysis (Paralytic Ileus)

National Center for Complementary and Integrative Health (NCCIH)

Phase 2 Terminated
100 enrolled

Neoplasms, Ileus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡